PROGRAM

CTAD Asia

Advanced Symposium in AD Clinical Trials

January 17–18, 2027

Singapore



OVERVIEW

January 17–18, 2027

TWO DAYS · SINGAPORE



DAY 1 SUNDAY JANUARY 17

09:00

WELCOME ADDRESS 08:45–09:00

SYMPOSIUM 1 09:00–09:40
Translating Brainshuttle™ technology into clinical advancement: trontinemab's path to Phase III

ORAL COMMUNICATIONS 09:40–10:45
OC01 – OC06

10:00

11:00

BREAK 10:45–11:15

KEYNOTE LECTURE 11:15–11:35
Jeffrey Cummings

INDUSTRY SYMPOSIUM 11:35–12:35
Eli Lilly & Company

12:00

LUNCH 12:35–13:35

13:00

LATE CALL ORAL COMMUNICATIONS 13:35–14:20
LC01 – LC04

14:00

ORAL COMMUNICATIONS 14:20–15:25
OC07 – OC12

15:00

KEYNOTE LECTURE 15:25–15:45
Cath Mummery

16:00

BREAK 15:45–16:10

LATE CALL ORAL COMMUNICATIONS 16:10–16:40
LC05 – LC07

BIOTECH SHOWCASE 16:40–17:00
3 companies

17:00

INDUSTRY SYMPOSIUM 17:00–17:30
XingImaging, a Mitro Company

DAY 2 MONDAY JANUARY 18

INDUSTRY SYMPOSIUM 08:30–09:30
Roche Diagnostics

KEYNOTE LECTURE 09:30–09:50
Sandrine Andrieu

ORAL COMMUNICATIONS 09:50–10:35
OC13 – OC15 · LC08

BREAK 10:35–11:05

LECTURE 11:05–11:20

INDUSTRY SYMPOSIUM 11:20–12:20
Eisai

LUNCH 12:20–13:20

ORAL COMMUNICATIONS 13:20–14:05
OC16 – OC19

SYMPOSIUM 2 14:05–14:45
Precision Medicine for Anti-Amyloid Therapy: From Risk Stratification to On-Treatment Biomarkers and Real-World Response

LATE BREAKING COMMUNICATION 14:45–15:05
Rachelle Doody

LATE CALL ORAL COMMUNICATIONS 15:05–17:00
LC09 – LC19

DAY 1

Sunday, January 17, 2027

PRELIMINARY PROGRAM · SINGAPORE



08:45
09:00

WELCOME ADDRESS

Official Welcome Address

Chong Yap Seng, National University of Singapore (Singapore)
Christopher Chen, National University of Singapore (Singapore)
Jacques Touchon, Montpellier University, Montpellier (France)
Bruno Vellas, Founding President IHU HealthAge, Toulouse (France)

09:00
09:40

SYMPOSIUM 1

Translating Brainshuttle™ technology into clinical advancement: trontinemab's path to Phase III

Chairperson: *Cath Mummery, University College London, London (United Kingdom)*

Presentation 1: Overcoming the blood–brain barrier in Alzheimer's disease: Mechanism, safety and biomarker efficacy of the Brainshuttle™ antibody trontinemab
Janice Smith, Roche Products Ltd, Welwyn Garden City (United Kingdom)

Presentation 2: Long-term treatment with trontinemab: interim findings from the open-label extension of the Brainshuttle™ AD study
Michael Woodward, Austin Health, Heidelberg, VIC (Australia)

Presentation 3: PrevenTRON: evaluating the effect of trontinemab in cognitively unimpaired individuals with biomarkers of Alzheimer's disease at high risk of clinical decline
Yi Tang, Xuanwu Hospital, Capital Medical University, National Center for Neurological Disorders, Beijing (China)

09:40
10:45

ORAL COMMUNICATIONS

09:40–09:45 · INTRODUCTION BY CO-CHAIRS
Oral Communications Session: Clinical Trials, Therapeutics and Interventions
Jeffrey Cummings, University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)
Atsushi Iwata, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo (Japan)

09:45 OC01 **Multistrain Probiotic Supplementation and Neurobiomarker Modulation in Alzheimer Disease–Related Cognitive Impairment: A Double-blind, Randomized, Controlled trial**
Kun Ho LEE · *Gwangju Alzheimer's Disease and Related Dementia Cohort Research Center, Chosun University, Gwangju, Korea, Republic of*

09:55 OC02 **Clinical Management Pathway for Subcutaneous Lecanemab Injection in Patients with Alzheimer's Disease: A Chinese Multidisciplinary Delphi Expert Consensus**
Jianping JIA · *Xuanwu Hospital, Capital Medical University, Beijing, China*

10:05 OC03 **Sodium Oligomannate Improves Cognitive function via Remodeling Gut Microbiome in Patients with Mild-to-moderate Alzheimer's Disease Dementia**
Heling CHU · *Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China*

10:15 OC04 **A Common Core, Tailored Delivery: Co-creating and Prototyping SINGER for Active Ageing Centres in Singapore**
Kwong Hsia YAP · *National University of Singapore, Singapore, Singapore*

10:25 OC05 **Multidimensional Evaluation of Cervical Shunting to Unclog cerebral Lymphatic Systems (CSULS) surgical procedure in Alzheimer's Disease: A 12-Month Single-arm Prospective Study**
Xia LI · *Shanghai Mental Health Center, Shanghai, China*

10:35 OC06 **Translating person-centered outcomes for AD trials: Cross-cultural feasibility of the ePSOM tool in Japanese memory clinics**
Yuki TAKEDA · *Kobe University Graduate School of Medicine, Kobe, Japan*

10:45 BREAK *Coffee Break, Exhibit Hall and Poster Sessions*

11:15 – 11:35

KEYNOTE LECTURE

Alzheimer's Disease: Emerging Therapeutics and Evolving Strategies

Jeffrey Cummings, University of Nevada Las Vegas (UNLV), Las Vegas, NV (United States)

Introduction: *Jiong Shi, The First Affiliated Hospital of USTC, Hefei (China)*



11:35 – 12:35

INDUSTRY SYMPOSIUM · ELI LILLY & COMPANY

Advancing the management of the Alzheimer's disease continuum: detection, diagnosis, and real-world experience

12:35 BREAK *Lunch, Exhibit Hall and Poster Sessions*

13:35 – 14:20

LATE CALL ORAL COMMUNICATIONS

13:35–13:40 · INTRODUCTION
Late Call Oral Communications Session

13:40 LC01 **POLARIS-AD Pivotal Phase 3 Results: Efficacy, Safety and Biomarkers Outcomes of Oral AR1001 in Early Alzheimer's Disease, Overall and Monotherapy Populations**
Fred KIM · *Aribio Co., Ltd., San Diego, United States*

13:50 LC02 **Longitudinal Proteomic Biomarkers of Anti-Amyloid Antibody treatment in Alzheimer's Disease**
Jintai YU · *Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China*

14:00 LC03 **Long-Term Outcomes with Lecanemab in Early Alzheimer's Disease in the Asian Region: Initial Findings Through 48-Months of Clarity AD Open-Label Extension**
Christopher CHEN · *Memory Aging and Cognition Center, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore*

14:10 LC04 **Rationale and design of TARBELA-AD: A Phase II, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of the NLRP3 inhibitor RG6434 in early symptomatic Alzheimer's disease**
Paul YATES · *Department of Geriatric Medicine, Austin Health, Melbourne, Australia*

14:20 – 15:25 · ORAL COMMUNICATIONS

14:20–14:25 · INTRODUCTION

Oral Communications Session: Clinical Trials, Biomarkers

***Lefkos Middleton**, Imperial College London, London (United Kingdom)*

14:25 OC07 **Dual White Matter Hyperintensity and p-tau217 Burden Is Associated with Cognitive Frailty and Longitudinal Decline**

Xin Tong TAN · *Memory, Ageing & Cognition Centre, National University Health System, Singapore, Singapore, Singapore*

14:35 OC08 **Proteomic Signatures of Cognitive Domains: Towards a Domain-specific Biomarker Framework**

Bang ZHENG · *Peking University, Beijing, China*

14:45 OC09 **Neuronal Pentraxin Receptor: a Disease-Specific Biomarker of Neurodegeneration and Clinical Progression Across Alzheimer's Disease Continuum**

Feng GAO · *The First Affiliated Hospital of USTC, Hefei, China*

14:55 OC10 **Diagnostic accuracy of Elecsys pTau181 and pTau217 plasma assays using global cutoffs in an Asian cohort: Results from the K-ROAD registry**

Jun Pyo KIM · *Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of*

15:05 OC11 **Plasma brain-derived pTau217 detects abnormal brain amyloid burden with high accuracy and predicts cognitive decline in a Singapore cohort**

Joyce R. CHONG · *Wisconsin Alzheimer's Disease Research Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, United States*

15:15 OC12 **Difference of Cerebrospinal Fluid Biomarkers and Neuropsychiatric Symptoms Profiles among Normal Cognition, Mild Cognitive Impairment, and Dementia Patient**

Ching-Chi HSU · *Wizcare Hospital, Taichung, Taiwan*

15:25 – 15:45 · KEYNOTE LECTURE

Emerging Therapeutic Pathways: Tau and Neuroinflammation

Cath Mummery, University College London, London (United Kingdom)

Introduction: *Yong Shen, The First Affiliated Hospital of USTC, Hefei (China)*



15:45 · BREAK

Coffee Break, Exhibit Hall and Poster Sessions

16:10 – 16:40 · LATE CALL ORAL COMMUNICATIONS

16:10 LC05 **Refining Plasma pTau217/Aβ42 Cutoffs for Amyloid Positivity in an Asian Cohort With High Cerebrovascular Disease Burden**

Amelia Ting Yu YAM · *Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore*

16:20 LC06 **Contributions of Vascular Risk Factors and AD pathology to White Matter Hyperintensity Burden and Progression in an Asian Memory-Clinic Cohort**

Yan LI · *Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore*

16:30 LC07 **Effects of kidney function on plasma p-Tau and brain-derived p-Tau levels and their diagnostic performance for amyloid PET positivity**

Chiew Yong NG · *Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore*

16:40 – 17:00

BIOTECH SHOWCASE

16:42 Biotech 1 **AriBio's Oral Therapeutic Pipeline for Alzheimer's Disease and Related Dementias: Phase 3 AR1001 and Phase 2a AR1005**
Fred KIM · *AriBio Co., Ltd., San Diego, United States*

16:48 Biotech 2 **Innovative MINC Technology for Treating Neurodegenerative Diseases**
Pauline LAU · *Suntec Medical, Walnut, United States*

16:54 Biotech 3 **REGEnLIFE: Advancing Brain–Gut Photobiomodulation to a Next-Generation Therapy for Healthy Brain Aging**
Volker HERRMANN · *REGEnLIFE, Paris, France*

17:00 – 17:30

INDUSTRY SYMPOSIUM · XINGIMAGING, A MITRO COMPANY

Empowering Radiopharmaceutical Clinical Development with Patient-Centric Phase 0 Clinical Studies

DAY 2

Monday, January 18, 2027

PRELIMINARY PROGRAM · SINGAPORE



08:30
09:30

INDUSTRY SYMPOSIUM · ROCHE DIAGNOSTICS

pTau217: Unlocking Scalable Early Detection in Alzheimer's Disease

Moderator: *Sraboni Sarkar, Global Medical Lead, Neurology, Roche Diagnostics, Rotkreuz (Switzerland)*

Speakers

Craig Ritchie, Founder and CEO of Scottish Brain Sciences and Professor of Brain Health and Neurodegenerative Medicine, University of St Andrews, Edinburgh (United Kingdom)

Alicia Algeciras, Professor of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN (United States)

Adeline Ng, Senior Consultant, National Neuroscience Institute, Singapore (Singapore)

09:30
09:50

KEYNOTE LECTURE

Lifestyle and Brain Health: What Does the Evidence Tell Us in 2027?

Sandrine Andrieu, IHU HealthAge/INSERM, Toulouse (France), and University of New Mexico, Albuquerque, NM (United States)

Introduction: *Christopher Chen, National University of Singapore (Singapore)*



09:50
10:35

ORAL COMMUNICATIONS

09:50–09:55 · INTRODUCTION

Oral Communications Session: Healthy Longevity

Bruno Vellas, IHU HealthAge, Toulouse (France)

09:55 OC13 **DL-Derived Neurodegenerative and Cerebrovascular Brain Ages Enhance Dementia Progression Prediction**

Yichi ZHANG · *Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore*

10:05 OC14 **Greater Modifiable Dementia Risk-Factor Burden Is Associated With Poorer Cognition and Higher Circulating p-Tau217 and Neurofilament Light Chain**

Reshma MERCHANT · *NUHS, Singapore, Singapore*

10:15 OC15 **Artificial Intelligence based Retinal Imaging Biomarker Identifies Suboptimal Brain Health and Improves Response to Lifestyle Intervention**

Yuan CAI · *Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China*

10:25 LC08 **Life-course social exposome shapes cognitive resilience across ageing populations in China and UK**

Xiaowen ZHOU · *Huashan Hospital, Fudan University, Shanghai, China*

10:35 — **BREAK** *Coffee Break, Exhibit Hall and Poster Sessions*

11:05 – 11:20

LECTURE

Healthy Longevity Grand Challenge

Tan Chorh Chuan, Chairman, Agency for Science, Technology and Research (A*STAR), and Chairman, MOH Office for Healthcare Transformation (Singapore)

Introduction: *Bruno Vellas, IHU HealthAge, Toulouse (France)*



11:20 – 12:20

INDUSTRY SYMPOSIUM · EISAI

12:20 — **LUNCH BREAK** *Lunch, Exhibit Hall and Poster Sessions*

13:20 – 14:05

ORAL COMMUNICATIONS

13:20–13:25 · INTRODUCTION

Oral Communications Session: Cerebrovascular Disease and Cognitive Impairment

Jacques Touchon, Montpellier University, Montpellier (France)

13:25 — OC16 **Multimodal subtyping reveals distinct subtypes of Alzheimer's and cerebrovascular disease**

Joanna Su Xian CHONG · *Centre for Sleep and Cognition & Centre for Translational Magnetic Resonance Research, Yong Loo Lin School of Medicine, National University of Singapore, Singapore*

13:35 — OC17 **From Incomplete Data to Detection: The Role of a Transformer-based Tabular Foundation Model in Cognitive Impairment Prediction**

Jing Jie TAN · *Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore*

13:45 — OC18 **Elecsys pTau217 plasma assay cutoff determination and validation for the detection of amyloid pathology in a Chinese population**

Yuyuan HUANG · *Huashan Hospital affiliated to Fudan University, Shanghai, China*

13:55 — OC19 **Peri-infusion Blood Pressure Reactivity during Lecanemab Treatment: A Cerebrovascular Signal in a Korean Real-World Cohort**

So Yeon JEON · *SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of*

14:05 – 14:45

SYMPOSIUM 2

Precision Medicine for Anti-Amyloid Therapy: From Risk Stratification to On-Treatment Biomarkers and Real-World Response

Chairperson: *Jiong Shi, College of Life Science and Medicine, University of Science and Technology of China, Hefei (China)*

Presentation 1: New Insights into the Genetic Basis and Plasma Biomarkers for Precision Medicine in Alzheimer's Disease

Takeshi Ikeuchi, Brain Research Institute, Niigata University, Niigata (Japan)

Presentation 2: Blood-Based Biomarkers and the Neuropathology of the Treated Brain: Evaluating Treatment Response for Precision Medicine in Alzheimer's Disease

Takeshi Iwatsubo, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Tokyo (Japan)

Presentation 3: Three Dimensions of Treatment Response — Cognitive Trajectory, Medial Temporal Atrophy, and Amyloid Clearance: Toward Precision Medicine in Alzheimer's Disease

Yuki Kujuro, Tachikawa Hospital, Tokyo (Japan)

14:45 – 15:05

LATE BREAKING COMMUNICATION

Preventing Alzheimer's Disease with Active Immunotherapy

Rachelle Doody, Axxium Life, Houston (United States)

15:05 – 17:00

LATE CALL ORAL COMMUNICATIONS

15:05–15:10 · INTRODUCTION

Late Call Oral Communications Session

15:10 LC09 **MRI-Derived Neurodegeneration Markers Improve Risk Stratification Beyond Plasma pTau217 in Preclinical Alzheimer's Disease**

Lili FANG · *Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong*

15:20 LC10 **Development of First-in-Human PET Radiotracer for Imaging γ-Secretase in Alzheimer's Disease**

Can ZHANG · *Massachusetts General Hospital and Harvard Medical School, Boston, United States*

15:30 LC11 **Head-to-Head Comparison of Plasma p-Tau217 and pTau217/Aβ42 Across Key Immunoassay platforms in an Asian Cohort with High Cerebrovascular Disease Burden**

Anqi TOH · *Memory, Aging and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore*

15:40 LC12 **The effects of brain amyloid burden and vascular risk factors on the distribution of cerebral microbleeds**

Jingjun CUI · *Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore*

15:50 LC13 **Gut-brain metabolic signatures in the Alzheimer's continuum: From clinical stratification to therapeutic targets**

Qiong WANG · *Department of Neurology, Institute on Aging and Brain Disorders, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, China*

16:00 LC14 **Concurrent validity of an automated speech biomarker for cognition (SB-C) in Mandarin-speaking older adults: interim results from a Beijing cohort**

Nicklas LINZ · *ki:elements, Saarbrücken, Germany*

16:10 LC15 **Associations of Vascular Risk Factors and Cognitive Performance with Cortical Regional Homogeneity in Middle-Aged to older Asian Adults**

Nisha SYED NASSER · *Saw Swee Hock School of Public Health, National University of Singapore, Singapore*

16:20 LC16 **Nasal Fluid Biomarkers from the Brain-Nose Interface as a Novel Minimally Invasive Tool for Alzheimer's Disease Research and Diagnosis**

Matthias LANGHORST · *Noselab GmbH, Munich, Germany*

16:30 LC17 **Donanemab for early symptomatic Alzheimer's disease: Amyloid PET dynamics**

Sergey SHCHERBININ · *Eli Lilly and Company, Indianapolis, United States*

16:40 LC18 **Prevalence and Correlates of High Dementia Risk Among 23,996 Community-Dwelling Older Adults: A Population-Based Stratified Screening Study in Northern China**

Xiaonan ZHANG · *First Hospital of Shanxi Medical University, Taiyuan, China*

16:50 LC19 **Long-term Extreme Cold Exposure and Incident Dementia in Older Adults with Socioeconomic Disparities: A COSMIC Collaborative Study**

Rui SONG · *Institute of Neurology, Huashan Hospital, Fudan University, Shanghai, China*

17:00 END OF THE CONFERENCE DAY

POSTERS

100 posters · 14 themes

GROUPED BY THEME · BY ABSTRACT NUMBER



01 Clinical Trials – Phase IIb & III

1 poster

00045 Dementia Alteration With the Neuroprotectant ergothioneine (DAWN): A Phase IIb biomarker-driven trial to evaluate the efficacy of ergothioneine to delay dementia onset and alter neurodegeneration.

Irwin K. CHEAH, Connie TEO, Ci Xian ANG, Mark LIM, Helen J. ZHOU, Mitchell K. P. LAI, Barry HALLIWELL, Christopher CHEN

Neurobiology Programme, Life Science Institute, National University of Singapore, Singapore, Singapore

02 Clinical Trials – Phase I & IIa

1 poster

00100 The Safety and Tolerability of Standard Dose Reverse Transcriptase Inhibitors in Patients with Mild Cognitive Impairment

Jit Hui Mark LIM, Deron HERR, Veronica HO, Paul GONZALES, Amelia YAM, Christopher CHEN, Jerold CHUN

Memory Ageing, and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore - Singapore (Singapore), Singapore, Singapore

03 Non-Pharmacologic and Multidomain Interventions

2 posters

00157 Cognitive effects of mind-body exercise in older adults with amnestic mild cognitive impairment: a systematic review and meta-analysis

Pei GENG, Jing Jun CUI

Singapore

00295 Trust is a Must in Patient care

Shalini NARCHAL

Northern Sydney Local Health District, Sydney, Australia

04 Imaging (MRI & PET)

9 posters

00037 APOE4 Sets an Earlier Amyloid Clock in Alzheimer's Disease

Han-Kyeol KIM, Daeun SHIN, Jae Hoon LEE, Joong-Hyun CHUN, You Jin KIM, Mina PARK, Young Hoon RYU, Chul Hyoung LYOO, Hanna CHO

Department of Neurology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of

00039 Risk Stratification of Cerebral Amyloid Angiopathy Using an Imaging-Based Composite Hemodynamic Score

Ashwati VIPIN, Abilash ELANGO, Nagaendran KANDIAH

Nanyang Technological University, Singapore, Singapore

00049 Regional cerebellar vulnerability associated with sleep phenotypes in the Alzheimer's disease spectrum

Suhyung KIM, Yoo Hyun UM

Department of Psychiatry, St.Vincent's Hospital, Suwon, Korea, Republic of

00088 Assessing the Heuron AD Automated Segmentation Tool: Validation and Predictive Performance in Comparison to FreeSurfer in a Memory Clinic Cohort

An Qi TOH, Fang JI, Juan ZHOU, Shin Hui ON, Vidishaa JALI, Ying Hui TENG, Jiangbo CUI, Eddie Jun Yi CHONG, Christopher Li-Hsian CHEN, Pei Ing NGAM

Memory, Ageing and Cognition Centre (MACC), Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, Singapore

00093 Beyond Hippocampal Atrophy: Quantitative MRI Phenotyping of Neurodegenerative and Vascular Contributions to Cognitive Impairment

Injoong KIM

Veterans Health Service Medical Center, Seoul, Korea, Republic of

00176 Cortical Microinfarcts during Anti-Amyloid-β Antibody Therapy: Relation to Amyloid-Related Imaging Abnormalities (ARIA)
Akisato NISHIGAKI, Hidehiro ISHIKAWA, Shotaro HORIE, Takaya UTSUNOMIYA, Naoko NAKAMURA, Kana MATSUDA, Yoshinori HIRATA, Hirofumi MATSUYAMA, Hiroyuki KAJIKAWA, Keita MATSUURA, Yuichiro II, Akihiro SHINDO
Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan

00230 Resting-state functional brain network topology of cognitive reserve in cognitively normal, amyloid-negative adults: a graph-theoretical study
Xiaonan ZHANG, Shu FANG, Yang LI
First Hospital of Shanxi Medical Universit, TAIYUAN, China

00251 White matter structural connectivity and structure–function coupling across cognitive reserve levels in cognitively normal, amyloid-negative adults
Xiaonan ZHANG, Shu FANG, Zhigang WANG, Xueyi WANG, Lingling WANG, Guowen MIN, Yang LI
First Hospital of Shanxi Medical Universit, TAIYUAN, China

00316 Magnetoencephalography-based neural oscillations and functional networks underlying working-memory in older adults with amyloid-β deposition
Xiaowen ZHOU, Yixiang ZHANG, Ming DING, Ding DING
Huashan hospital, Fudan University, Shanghai, China

05 Biomarkers (CSF & Plasma)

26 posters

00014 Integrating Plasma GFAP, NfL, and p-Tau181 for Mild Cognitive Impairment Detection: An Exploratory Machine Learning Study
Hong GUO, Xiao XIAOHUA
Department of Geriatrics, Shenzhen Second People's Hospital (The First Affiliated Hospital of Shenzhen University), Shenzhen, China

00018 Baseline Plasma C1q and C3 as Potential Biomarkers for Lecanemab Efficacy and ARIA Risk in Early Alzheimer's Disease
Dong Woo KANG
Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of

00020 Sex Differences in the GFAP–Cognition Association: A Cross-Sectional Study in a Shenzhen-Based Chinese Cohort
Chunhua LIANG, Xiaohua XIAO
Shenzhen Second People's Hospital, Shenzhen City，guangdong Province, China

00029 Machine Learning–Enabled Plasma Multi-Panel Biomarker Model Improves Amyloid Detection and Cognitive Staging for Alzheimer's Disease Assessment
Yuan CAI, Yuen Tung NG, Ying Hong CHAN, Wing Yin CHAN, Huijing ZHENG, Adrian WONG, Jize WEI, Mandy Yuen Ting LAU, Lili FANG, Ho KO, Lin CAO, Vincent Chung Tong MOK
Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China

00042 The role of Glial Fibrillary Acidic Protein as a predictor of cognitive decline independent of amyloid and cardiovascular risk: Biomarker and Cognition Study, Singapore
Chen CUI, Jessie Siew-Pin LEUK, Deneshan PERANANTHARAJAH, Nagaendran KANDIAH
DRCS, Singapore, Singapore

00060 Plasma p-tau217 measured by an enzyme-free digital immunoassay discriminates amyloid PET status in patients with cognitive impairment
Eunwon LEE, Hyuk Sung KWON, Seungyeon HAN, Kwangho CHOI, Eun Sun PARK, Hee-Jeong KIM, Jeong-Min BAEK, Min-Ju KIM, Mina HWANG, Hyun-Hee PARK, Juhwan PARK, Hyundoo HWANG, Seong-Ho KOH
Bredis Healthcare Inc., Seoul, Korea, Republic of

00067 Inflammatory proteomic signatures associated with longitudinal cognitive performance in an Asian population
Manasa YOGEESH, Lam-Quang NGUYEN, Yeu Hann LEE, Nisha SYED NASSER, Matthew PASE, Mitchell K. P. LAI, Saima HILAL
Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore, Singapore, Singapore

00068 Associations between plasma p-tau181 and NfL and cognition in a community-based cohort: SINGER Study
Amelia Ting Yu YAM, Yuek Ling CHAI, Kwong Hsia YAP, Joyce Ruifen CHONG, Fang JI, Juan Helen ZHOU, Mitchell Kim Peng LAI, Christopher Li Hsian CHEN
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

00102 Plasma p-Tau217 Guided Screening for Anti-Amyloid Treatment Eligibility and Uptake in an Asian Memory Clinic Cohort
Jit Hui Mark LIM, Alfeo Julius SY, Si Ying WONG, Paul GONZALES, Grace LIN, Joyce CHONG, Mitchell LAI, Christopher CHEN
Memory Ageing, and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

00107 Impact of Plasma p-Tau217 Results on Diagnosis and Diagnostic Confidence, in a Memory Clinic Cohort
Jit Hui Mark LIM, Alfeo Julius SY, Paul Nichol GONZALES, Grace LIN, Si Ying WONG, Joyce CHONG, Mitchell LAI, Christopher CHEN
Memory Ageing, and Cognition Centre, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

00114 A Six-protein Plasma Biomarker Panel Complements pTau217 in Cases of Diagnostic Uncertainty
Monika CHAUHAN, Yi Jayne TAN, Shermyn X. NEO, Teresa H.L. LEONG, Rebeca H.M. HOE, Uyen Le Ngoc HA, Hui Jin CHIEW, Shahul HAMEED, Kok Pin NG, Simon K. S. TING, Adeline Su Lyn NG
National Neuroscience Institute, Singapore, Singapore

00122 Clinical performance of BREDIS DIA P-tau217 for predicting amyloid PET status in patients with mild cognitive impairment or mild dementia
Seungyeon HAN, Hyuk Sung KWON, Eunwon LEE, Eun Sun PARK, Jeong-Min BAEK, Min-Ju KIM, Hyun-Hee PARK, Hyundoo HWANG, Seong-Ho KOH
Bredis Healthcare Inc., Seoul, Korea, Republic of

00145 The Potential Clinical value of CSF DOPA Decarboxylase for Differentiating Lewy Body Disease from Alzheimer's Disease
Ryosuke SHIMASAKI, Masanori KURIHARA, Emiko KIKKAWA-SAITO, Shereyasee DAS, Megan DE PAUW, Erik STOOPS, Atsushi IWATA
Department of Neurology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan

00158 Temporal Evolution Characteristics and Temporal Relationship of Brain Tau Seeding Activity, Tau Phosphorylation, Tau Pathology and Behavioral Changes in 3x-Tg Mice
Yajie LIU, Chengsi WU
The First Affiliated Hospital of Nanchang University, nanchang, China

00166 Longitudinal Proteomic and Metabolomic Alterations following 6-months Lecanemab Therapy in AD
Yiliang LIU, Haokun LIU, Mengyuan XIONG, Keying FANG, Weiwei ZHANG, Lu SHEN, **Bin JIAO**
Xiangya Hospital, Central South University, Changsha, China

00170 Serum TRAIL during 18 months of lecanemab treatment in Alzheimer disease
Xiaohan SUN, Shuangwu LIU, Yi LI
Qilu Hospital of Shandong University, Jinan, China

00174 Preferences and access considerations for clinical adoption of blood-based biomarker tests to confirm amyloid-β pathology in early Alzheimer's disease: a 12-country survey
Amitabh DASH, Temmei ITO, Gandan JIANG
Eisai (Singapore) Pte Ltd.,, Singapore, Singapore

00222 The incremental value of plasma p-Tau/Aβ42 ratio versus p-Tau alone for detecting abnormal brain amyloid burden
Chiew Yong NG, Mei SHIH, Mitchell Kim Peng LAI, Christopher Li Hsian CHEN, Joyce Ruifen CHONG
Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

00236 Validation of a Novel Plasma p-Tau217 Detection Method: A Pilot Study
Cai YUAN, Lau WING YAN, Li YAN, Jin GAOWEI, Chen JING, Fang LILI, Mok VINCENT C.T, Ko HO
Lau Tat-chuen Research Centre of Brain Degenerative Diseases in Chinese, Gerald Choa Neuroscience Institute, Therese Pei Fong Chow Research Centre for Prevention of Dementia, Lui Che Woo Institute of Innovative Medicine, Li Ka Shing Institute of Health Sciences, NA, Hong Kong

00239 Lecanemab Improves Alzheimer's Disease-Associated Sleep Disturbances
Hao HU, **Yi QU**, Lan TAN
University of Health and Rehabilitation Sciences, Qingdao, China

00247 Plasma proteomics biomarkers for staging and predicting Alzheimer's clinical continuum: A Multicenter Study in China
Dan YANG, Hui ZHAO, Zhu XIAOLEI, Hu ZHEQI, Mao CHENGLU, Xu YUN
Nanjing Drum Tower Hospital, Nanjing, China

00266 Lecanemab regulates the extracellular immune secretion protein pathway in the plasma of Alzheimer's disease patients: A related study on plasma proteomics after 6 months of treatment
Hu HUA, Liu SHANWEN, Wang JIJING, Fang PAN, Li FANGBO, Zeng QI
The Second Affiliated Hospital of Soochow University, Suzhou, China

00268 Health Economic Evaluation of a Sequential Plasma p-tau181 and p-tau217 Diagnostic Pathway for Alzheimer's Disease in China
Weineng CHEN, Jun MENG, Yingjun OUYANG, Xianfei ZENG, Xinyu ZHAO, Zhong PEI, Haiyin WANG
Shanghai Health Development Research Center, Shanghai, China

00287 Serum Proteomic Signatures of Cognitive Impairment in White Matter Hyperintensities and Their Associations With Longitudinal Cognitive Decline
Yun XU, **Chenglu MAO**
Nanjing Drum Tower Hospital, Nanjing, China

00300 Expanded Alzheimer's Disease Pathway Coverage and Enhanced Disease-Relevant Biomarker Detection with NULISAseq™ Neuro 220 While Preserving Continuity with CNS 120
Ser Mien CHIA, Nicholas HO
MSD Singapore, Singapore, Singapore

00325 Bone- and Senescence-Related Plasma Proteins Across Cognitive Impairment in the Global Neurodegeneration Proteomics Consortium
Ting ZHAI, Michael SNYDER, Victor HENDERSON, Tony WYSS-CORAY, **Vidyani SURYADEVARA**, Gnpc THE GLOBAL NEURODEGENERATION PROTEOMICS CONSORTIUM
Stanford University, Stanford, United States

06 Vascular Cognitive Impairment & Cerebrovascular Disease

6 posters

00084 Coronary and Carotid Atherosclerosis Are Synergistically Linked to Frontal Brain Free-Water Abnormalities
Fang JI, Benjamin Yq TAN, Mayank DALAKOTI, Voon Hao LEW, Christy Jh ANG, Vijay Kumar SHARMA, Xi Zhen LOW, Ren Wei LIU, Andrew MAKMUR, Lynette TEO, Xingfeng SHAO, Danny J. J. WANG, Roger Sik Yin FOO, Juan Helen ZHOU
Centre for Sleep and Cognition; Centre for Translational Magnetic Resonance Research; Healthy Longevity and Human Potential Translational Research Programme; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore

00106 Association between global cerebrovascular burden and incident apathy in southeast Asian older adults without dementia
Yingqi LIAO, Eishwar RAVICHANDRAN, Mark LIM, Jiangbo CUI, Joyce CHONG, Mitchell LAI, Saima HILAL, Xin XU, Christopher CHEN
Memory Aging and Cognition Centre, Department of Pharmacology, National University of Singapore, Singapore, Singapore

00131 The Retinal Microvasculature Global Composite (RMGC) Score: Correlation to Long Term Cardiovascular Outcomes and Vascular Cognitive Impairment
Shu Jie TING, Ashwati VIPIN, Deneshan PERANANTHARAJAH, Nagaendran KANDIAH
Lee Kong Chian School of Medicine, Nanyang Technological University, , Singapore

00188 Structural Carotid Atherosclerosis and Mild Behavioral Impairment: A Cross-sectional Study in a Community-dwelling Population
Po-Han CHEN, Yi-Ya FANG, Yen-Ju LIN, Mei-Feng HUANG, Yi-Chun YEH, Hsiu-Fen LIN, Cheng-Sheng CHEN
Department of Psychiatry, Kaohsiung Medical University Gangshan Hospital, Kaohsiung Medical University, Kaohsiung City, Taiwan

00212 Multimodal Cortical Hierarchy Reorganization and Plasma Biomarkers in Cerebral Small Vessel Disease
Jingxian XU, Xu YUN
Department of Neurology, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China

00311 Association between plasma P-tau181 level and step width in patients with cerebral small vessel disease
Yuting MO, Yun XU
Nanjing Drum Tower Hospital, Nanjing, China

07 Artificial Intelligence & Data-Driven Innovation

5 posters

00092 GLoMeD: Global and Local Medical Knowledge Distillation via LLM for Alzheimer's Disease Longitudinal Studies
Tingyu MO, Jacqueline C.K LAM, Victor O.K. LI, Yang HAN, Lawrence Y. L. CHEUNG
The University of Hong Kong, , China

00118 Beyond Diagnostic Codes: Large Language Model-Based Cognitive Phenotyping From Multidisciplinary Hospital Documentation
Emily YEE, Alicia LAM, Francis PHNG, Tudor GROZA, Lydia AU, Yao Feng CHONG, Li Feng TAN, **Benjamin Yq TAN**
National University Hospital, Singapore, Singapore

00204 Can routine fundus photographs separate cognitive impairment from screening controls, and dementia from mild cognitive impairment? A two-stage retinal AI study
Ahn SOO HO, Park KISEOK, Park MIN KI, Ahn GEUN HOE, Hong JUN HO, Kim CHEOL MIN, Hwang GYU YEON, Jung NA-YEON, Lee JIWOONG
Department of Integrative Medicine, Yonsei University College of Medicine, Seoul, Korea, Republic of

00255 Improving the Process Quality of Anti-Amyloid Therapy Through Digital Closed-Loop Management: A Real-World Before-and-After Study
Shu FANG, Xiaonan ZHANG, Guowen MIN, Lianghao SI, Yang LI
The First Hospital of Shanxi Medical University, Taiyuan, China

00306 Automated Brain Region Segmentation in Histological Sections Using Multimodal Foundation Modeling
Ser Mien CHIA, Kelvin CHONG
MSD Singapore, Singapore, Singapore

08 Epidemiology

11 posters

00041 Cumulative Cardiometabolic Burden and Cognitive, Neuroimaging, and Plasma Biomarker Correlates in the BIOCIS Study
Natalie Jian-Ting WEE, Pricilia TANOTO, Faith Phemie Hui En LEE, Shan Yao LIEW, Angelica KRESTIANTO, Chen CUI, Kiirtaara ARAVINDHAN, Nagaendran KANDIAH
Dementia Research Centre (Singapore), Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore, Singapore

00064 Associations of APOE ε4 with cognition and neuroimaging markers in an Asian population-based setting
Yeu Hann LEE, Jiannan HUANG, Lam Quang NGUYEN, Manasa YOGEESH, Nisha SYED NASSER, Gurveen KAUR SANDHU, Jacklyn LEONARDO, Fatin ZAHRA BINTE ZAILAN, Narayanaswamy VENKETASUBRAMANIAN, Nagaendran KANDIAH, Saima HILAL
Saw Swee Hock School of Public Health, , Singapore

00089 Association between Sleep Quality with Cognitive Function: Singapore Health Study 2
Nguyen LAM-QUANG, Goh Jie Lin CLAIRE MARIE, Huang XIANGYUAN, Sim XUELING, Hilal SAIMA
Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore

00095 Longitudinal associations between lifestyle changes and cognitive decline in an Asian cohort
Saima HILAL
National University of Singapore, , Singapore

00129 Differential Associations of Alzheimer's Disease Risk Factors with Spatiotemporal Orientation in Cognitively Unimpaired Adults
Lidor GAZIT, Elad YUNDLER, Uri ELIAS, Gad A. MARSHALL, Shahar ARZY
The Hebrew University of Jerusalem, Jerusalem, Israel

00149 Incidence and Baseline Factors Associated with First Pneumonia after Alzheimer's Disease Diagnosis: A Retrospective Cohort Study in Singapore
Li Feng TAN, **Shing Yee KOH**
Yong Loo Lin School of Medicine, Singapore, Singapore

00151 The Association between healthy lifestyle and cognitive decline with all-cause mortality, cardiovascular and cerebrovascular disease mortality: a 10-year, population-based, prospective cohort study
Chaobo BAI, **Junliang YUAN**
peking university sixth hospital, Beijing, China

00190 Associations of Sarcopenia-Related Measures with Cognitive Impairment in Older Adults Aged ≥65 Years: A Cross-Sectional Study
Yang LI, **Wangshu DAI**, Yafei ZHENG, Fuchao LI, Dan RONG, Lei QIAN, Shanshan LI
Department of Geriatric Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008, China, Nanjing, China

00269 A Rapid Community-Based Screening CatBoost Model for Mild Cognitive Impairment: Development and External Evaluation
Yun* XU, **Shanshan LI**, Zhihong KE, Xicheng CHEN, Wangshu DAI, Chenglu MAO, Longjie QV, Yang ZHAO
Department of Geriatrics, Nanjing Drum Tower Hospital, The Affiliated Drum Tower Clinical College of Nanjing Medical University, Nanjing, China, Nanjing, China

00272 Factors Associated with Cognitive Impairment and Development of a Machine Learning Prediction Model Among Community-Dwelling Older Adults in Northern China
Lingling WANG, Xiaonan ZHANG, Yang LI
Shanxi Medical University, Taiyuan, China

00320 Development of an MCI Risk Prediction Model Based on Clinical Characteristics, MMSE Subdomain Scores, Plasma p-tau217, and Sarcopenia-Related Indicators
Shanshan LI, Wangshu DAI, Dan RONG, Zhihong KE, Li YANG*
Department of Geriatrics, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, Nanjing

09 Non-Clinical, Early Discovery & Mechanistic Research

9 posters

00010 Neuroprotective Effects of Niclosamide Piperazine in an Intracerebroventricular Streptozotocin Rat Model of Sporadic Alzheimer's Disease

Aylin JAFARI, Maryam NAZARI, Amir BARZEGAR BEHROOZ, Ahmad Reza DEHPOUR, Javad FAHANIK BABAEI

School of Medicine, Tehran University of Medical Sciences, Tehran, Iran, Tehran, Iran, Islamic Republic of

00022 Polydopamine Modified with Brain Targeting Peptide RVG for Treatment of Alzheimer's Disease by Inhibiting Oxidative Stress and Inflammatory Response

Heling CHU, Chuyi HUANG

Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

00051 Association Between Plasma GFAP and AI Based Fundus Analysis for Dementia Risk Estimation

Yuan CAI, Yuen Tung NG, Ying Hong CHAN, Wing Yin CHAN, Huijing ZHENG, Adrian WONG, Mandy Yuen Ting LAU, Lili FANG, Anran RAN, Ho KO, Carol Yim Lui CHEUNG, Vincent Chung Tong MOK

Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong, China

00053 Compound K Restores Opposing Store-Operated Calcium Entry Dysregulation in Neurons and Astrocytes Under Neurodegenerative Stress

Geun Hee SEOL

Korea University, Seoul, Korea, Republic of

00104 A CNS Drug Delivery System for Neurodegenerative Diseases

Chun-Ting (Isaac) CHENG, Pauline LAU

Suntec Medical, Walnut, United States

00297 From gum to brain: Porphyromonas gingivalis gingipain drives microglial inflammation and dysfunction with glycogen synthase kinase-3β activation

Mika FUJII, Aoi IKEDO, Kaito MIZUNO, Wataru MINAMIZONO, Akira HASEBE, Mariko NAITO, Yutaka WATANABE, Ji-Won LEE

Biochemistry, Department of Oral Health Science, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Japan

00298 Pyk2 inhibition drives a β-amyloid-responsive, non-inflammatory microglial state

Kaito MIZUNO, Aoi IKEDO, Wataru MINAMIZONO, Koichi NAKAMURA, Ji-Won LEE

Pediatric and Special Care Dentistry, Department of Oral Functional Science, Graduate School of Dental Medicine, Hokkaido University, Sapporo, Japan

00302 A Human iPSC-Derived Microglial Phagocytosis Assay Enables Quantitative Evaluation and Differentiation of Amyloid-β Uptake Agonists for Alzheimer's Disease Drug Discovery

Ser Mien CHIA, Alex CHOJNOWSKI

MSD Singapore, Singapore, Singapore

00308 NULISA Plasma Proteomics Reveals Translational Biomarker Signatures of Disease Progression Across Amyloidopathy Models

Ser Mien CHIA, Dean LEE

MSD Singapore, Singapore, Singapore

11 Cognitive & Functional Outcomes

3 posters

00202 Effect of baseline amyloid levels on cognitive decline in adults with preclinical Alzheimer's disease enrolled in the A4 clinical trial, measured with composite scores from the Cogstate Brief Battery

Paul MARUFF, Karra HARRINGTON, Casey VANDERLIP, The A4 STUDY TEAM

Cogstate, Mellbourne, Australia

00217 Prefrontal Phase Slope Index During an Auditory Oddball Task: Associations with Amyloid Burden and Cognitive Performance

Jang-Han BAE, Min-Ho CHOI, Jai Jun CHOUNG, Jae-Young HA, Hye-Sung MOON, Vitella FOMENKO, Tanya XI, Fred KIM, Chang-Ho SHIN

Korea Institute of Oriental Medicine, Daejeon, Korea, Republic of

00274 Rater Performance Central Monitoring in Alzheimer's Disease Trials: Detecting Administration and Scoring Errors on Clinical Outcome Assessments

Robyn LEVENTHAL, Karra HARRINGTON, Charles O'CONNOR, Paul MARUFF

Cogstate, Melbourne, Australia

12 Digital Endpoints, Remote Monitoring & Connected Health

6 posters

00186 From Digital Drawing to Corticomuscular Coupling: Preliminary Community Findings and a Wearable EEG–EMG Framework for Investigating Cognitive Preservation in Alzheimer's Disease

Haitao LI, Huan ZHAO

Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

00199 One speech model across two languages for the Alzheimer's dementia against mild cognitive impairment step, and what multinational trials need to calibrate

Adrian ORTIZ, Aggelos IOANNIDIS, Lisa CHIANG

Cephalgo, Strasbourg, France

00200 Digital cognitive assessments discriminate early tau pathology in cognitively unimpaired older adults

Karra HARRINGTON, Casey VANDERLIP, The A4 STUDY GROUP, Paul MARUFF

Cogstate, Melbourne, Australia

00243 Cross-lingual validation of the automated Speech-based Biomarker for Cognition (SB-C) in Korean older adults

Hyunsun HAM, Seungjae CHOI, Elio INGOLD, Hee Won YANG, Jeong Lan KIM, Minwoo CHO, So Yeon JEON, Johannes TRÖGER, Louisa SCHWED, Nicklas LINZ, Alexandra KÖNIG

Department of Psychiatry, Seoul Metropolitan Government-Seoul National University (SMG-SNU) Boramae Medical Center, Seoul, Korea, Republic of

00253 **Smart ring–derived rest–activity rhythm, sleep, and nocturnal physiology in relation to plasma p-tau217, GFAP, and NfL in a community dementia care setting: a pilot study**

Seungyeon HAN, Eun Sun PARK, Hye Won KIM, Hyundoo HWANG, Dong Woo KANG

Bredis Healthcare Inc., Seoul, Korea, Republic of

00322 **Eye Movement Assessment of Early Efficacy of Lecanemab in Alzheimer's Disease: A Pilot Study**

Shu FANG, **Xiaonan ZHANG**, Guowen MIN, Wenjing BAO, Junpin AN, Lianghao SI, Xuejiao CHEN, Yang LI

First Hospital of Shanxi Medical Universit, TAIYUAN, China

13 New Hypotheses & Novel Therapeutic Approaches

2 posters

00057 **Rapid reversal of amyloid and myelin pathology following deep cervical lymphatic–venous anastomosis in Alzheimer's disease**

Xu WANG, Yongtao LIU, Jinxiang LIU, Rongyi WANG, Jing ZHENG, Zhiyang DENG, Kunxiu SONG, Daijie ZHANG, Chunwei WANG, Kai ZHU, **Yanming WANG**

Shandong Medical and Pharmaceutical University, Binzhou, China

00215 **Protecting and Restoring Glutamatergic Synapses Through Planar Cell Polarity Signaling in Alzheimer's Disease**

Yimin ZOU

Uinversity of California, San Diego, La Jolla, United States

14 Healthy Longevity, Physical Health, Brain Health & AD Prevention

5 posters

00072 **Association Between Changes in Brain Care Score and Memory Recall Performance: Findings from the Queenstown Health District Cohort**

Alicia HOW, Xin Xiang LEE, Shuna KHOO, Benjamin TAN, Lile JIA, Li Feng TAN

National University of Singapore, , Singapore

00141 **Social Integration Is Associated With Neuropsychiatric Outcomes in Older Adults With Cognitive Dysfunction**

Moon Ho PARK, Joo Young MIN

Korea University Ansan Hospital, Ansan, Korea, Republic of

00228 **Modifiable determinants of cognitive reserve in community-dwelling middle-aged and older Chinese adults: a cortical-thickness residual approach**

Xiaonan ZHANG, Zhigang WANG, Guo XINGYI, Li YANG

First Hospital of Shanxi Medical Universit, TAIYUAN, China

00290 **Photobiomodulation and the Hallmarks of Aging: From Neurodegenerative Disease to Healthy Brain Longevity**

Guillaume BLIVET, Cédric BERTRAND, Marwan SABBAGH, **Jacques TOUCHON**

University of Montpellier, Montpellier, France

00292 **Decomposing the ageing effect in Alzheimer's disease into genetic, epigenetic and wearable layers**

Hyeonseul PARK, Yoontae KIM, Jeong YEON-OH, **Gim JUNGSOO**

Chosun University, Gwangju, Korea, Republic of

15 Real-World Data, Registries & Implementation Science

14 posters

00033 **Initial Multicenter Real-World Experience of Lecanemab Therapy in Early Alzheimer's Disease: A Three-Regional Hospital Study in Taiwan**

Hsu JUNG LUNG, Sun YU, Liu YI-CHIEN

New Taipei Municipal TuCheng Hospital, Taipei, Taiwan

00153 **Association of ARIA with Cognitive Changes and Amyloid Reduction During Anti-Amyloid Antibody Therapy**

Hidehiro ISHIKAWA, Kana MATSUDA, Takaya UTSUNOMIYA, Yoshinori HIRATA, Hirofumi MATSUYAMA, Kosuke SAKAE, Akisato NISHIGAKI, Naoko NAKAMURA, Hiroyuki KAJIKAWA, Keita MATSUURA, Yuichiro II, Akihiro SHINDO

Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan

00154 **Real-world safety with Donanemab: An initial experience from Singapore**

Nicolle Marie CHEW, Abraham LEE, Kim En LEE

Ministry of Health Holdings (MOHH), Singapore, Singapore, Singapore

00160 **Real-world safety and biomarker outcomes with Lecanemab in Singapore: An analysis of the very elderly cohort**

Abraham LEE, Nicolle CHEW, Kim En LEE

Ministry of Health Holdings (MOHH), Singapore, Singapore, Singapore

00162 **Establishment and Initial Enrollment of a Nationwide Registry for Cerebral Amyloid Angiopathy-Related Inflammation and Treatment-Associated Amyloid-Related Imaging Abnormalities in Japan: The ARIAHAN Registry**

Akihiro SHINDO, Hidehiro ISHIKAWA, Akisato NISHIGAKI, Yusuke YAKUSHIJI, Tomoyuki OHARA, Soichiro SHIMIZU, Kensuke OKADA, Yuishin IZUMI, Kensaku KASUGA, Kenichiro SATO, Kosuke KUDO, Takeshi IKEUCHI, Atsushi IWATA, Ryoko IHARA

Department of Neurology, Mie University Graduate School of Medicine, Tsu, Japan

00194 **Anti- amyloid Therapy Improve Subjective Sleep Quality and Reduce Plasma p-tau217 Levels in Early Alzheimer's Disease：A 1-year Follow-up Real-world Study**

Shujun FENG, Peikun HE, Yuhu ZHANG, Lijuan WANG

Guangdong Provincial People's Hospital, Guangzhou, China

00209 **Real-World Safety, ARIA Profile, and Clinical Experience of Lecanemab Therapy in Early Alzheimer's Disease: Initial 50-Patient Cohort from King Chulalongkorn Memorial Hospital**

Yuttachai LIKITJAROEN, Pakapon SUESATCHAPONG, Peerapon WATCHALAYANN, Thawin VASURATNA, Tara RAK-AREEKUL, Yuthachai SARUTIKRIANGKRI, Nantaporn PITAKVEJ, Pharewa KAEWMANEE, Phenphichcha CHUCHUEN, Alissara TAITHONG, Thanakit PONGPITAKMETHA, Thachamai SMITASIRI

Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

00223 **Patient and Care Partner Perspectives on Lecanemab Treatment in Japan: A Questionnaire-Based Study**

Atsushi IWATA, Ryoko IHARA, Mariko ENDO, Takayuki ISHIDA, Hiroki KAMAKURA, Hisayuki IWATA, Yuich MARUKI
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan, Tokyo, Japan

00225 **Anti-Amyloid Monoclonal Antibody Treatment for Alzheimer's Disease in China: A National Multicenter Study**

Jin-Tai YU, Ling-Ling LI
Huashan Hospital, Shanghai Medical College, Fudan University, shanghai, China

00244 **Neuropsychiatric symptom trajectories during routine lecanemab treatment in older Chinese adults with Alzheimer's disease: a single-center psychiatry-led real-world study**

Zhengluan LIAO, Dansheng LE
Center for Rehabilitation Medicine, Department of Psychiatry, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China

00257 **Sustained SGLT2 Inhibitor Use and Risk of Alzheimer's Disease and Dementia in Older Adults With Type 2 Diabetes: A Landmark Analysis From the LIFE Study**

Hisashi NOMA, Taiki SUGIMOTO, Takao FUJISAWA, Futoshi ODA, Megumi MAEDA, Haruhisa FUKUDA
Department of Interdisciplinary Statistical Mathematics, The Institute of Statistical Mathematics, Tokyo, Japan

00262 **Standardized Diagnostic Pathways and Multilevel Quality-Control Systems for Alzheimer's Disease: A Cross-National Implementation Science Review Toward Precision and Equity**

Xingyi GUO, Yang LI
The First Hospital of Shanxi Medical University, Taiyuan, China

00279 **Longitudinal Plasma p-tau217 and Proteomic Correlates of Lecanemab Pharmacodynamic Response in a Real-World Chinese Alzheimer's Disease Cohort**

Wang LIAO, Xiangyi LUO, Bin CHEN, Qinggan ZENG, Yang LI, Haiqun XIE, Liangyu ZOU, Ziyu SHE, Han LIN, Chenyang WANG, Ying YANG, Guihua LI, Yong YOU, Yu TU, Jun LIU
The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China

00310 **Associations of baseline MRI characteristics with ARIA during donanemab treatment: A real-world single center experience**

Ta-Fu CHEN, **Cheng-Hsuan LI**
Department of Neurology, National Taiwan University Hospital, Taipei City, Taiwan

Notes

Notes

Our partners

CTAD Asia 2027 is made possible thanks to the support of our partners.

PLATINUM PARTNERS

Eisai

Lilly

Roche

GOLD PARTNER

XingImaging

A Wholly Owned Subsidiary of MITRO Biotech Co., Ltd. Mitro

SILVER PARTNERS

BREDIS Healthcare

Bristol Myers Squibb®

Cogstate

INSTITUTIONAL PARTNER

NUS National University of Singapore

Yong Loo Lin School of Medicine

CTAD Asia 2027

JANUARY 17–18, 2027 · SINGAPORE

17th Clinical Trials on Alzheimer's Disease Conference

